Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes

被引:26
作者
Ivashchenko, Y
Kramer, F
Schäfer, S
Bucher, A
Veit, K
Hombach, V
Busch, A
Ritzeler, O
Dedio, JR
Torzewski, J
机构
[1] Univ Ulm, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany
[2] Aventis Pharma Deutschland GmbH, DG Cardiovasc Res, Frankfurt, Germany
关键词
atherosclerosis; C-reactive protein; drug development; gene expression; protein kinase C;
D O I
10.1161/01.ATV.0000150041.81963.68
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - C-Reactive protein (CRP) is the prototype acute phase protein and a cardiovascular risk factor. Interleukin-1beta (IL-1beta) and IL-6 stimulate CRP synthesis in hepatocytes. We searched for additional pathways regulating CRP expression. Methods and Results - Primary human hepatocytes (PHHs) were treated with IL-1beta, IL-6, and protein kinase C (PKC) activator phorbol 12,13-dibutyrate (PDBu). CRP was analyzed by quantitative RT-PCR and ELISA. PDBu significantly induced CRP transcription by 21.0+/-9.24-fold and protein release by 2.9+/-0.5-fold. Transcriptional regulation was studied in detail in hepatoma G2 (HepG2) cells stably transfected with the 1-kb CRP promoter (HepG2-ABEK14 cells). In these cells, PDBu significantly induced CRP transcription by 5.39+/-0.66-fold. Competetive inhibition with bisindolylmaleimide derivative LY333531 abolished PDBu-mediated promoter activation. Competetive inhibition with IkappaB kinase inhibitor I229 also inhibited PDBu effects. Importantly, IL-8 significantly induced CRP release in PHHs by 58.675+/-19.1-fold, which was blockable by LY333531. Conclusions - This study describes a novel PKC-dependent transcriptional regulation of CRP gene expression, which, in analogy to the classical IL-1beta and IL-6 pathways, is operational in hepatocytes only. It also identifies IL-8 as a potential physiological PKC activator. HepG2-ABEK14 cells may be useful for high throughput screening to identify inhibitors of CRP synthesis for the prevention of cardiovascular disease.
引用
收藏
页码:186 / 192
页数:7
相关论文
共 39 条
[1]   Possible protective role for c-reactive protein in atherogenesis - Complement activation by modified lipoproteins halts before detrimental terminal sequence [J].
Bhakdi, S ;
Torzewski, M ;
Paprotka, K ;
Schmitt, S ;
Barsoom, H ;
Suriyaphol, P ;
Han, SR ;
Lackner, KJ ;
Husmann, M .
CIRCULATION, 2004, 109 (15) :1870-1876
[2]   Modulation of atherogenesis by chemokines [J].
Boisvert, WA .
TRENDS IN CARDIOVASCULAR MEDICINE, 2004, 14 (04) :161-165
[3]   Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells [J].
Calabró, P ;
Willerson, JT ;
Yeh, ETH .
CIRCULATION, 2003, 108 (16) :1930-1932
[4]   INDUCIBLE AND TISSUE-SPECIFIC EXPRESSION OF HUMAN C-REACTIVE PROTEIN IN TRANSGENIC MICE [J].
CILIBERTO, G ;
ARCONE, R ;
WAGNER, EF ;
RUTHER, U .
EMBO JOURNAL, 1987, 6 (13) :4017-4022
[5]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397
[6]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[7]   Missing pieces in the NF-κB puzzle [J].
Ghosh, S ;
Karin, M .
CELL, 2002, 109 :S81-S96
[8]   Human hepatocytes as a tool for studying toxicity and drug metabolism [J].
Gómez-Lechón, MJ ;
Donato, MT ;
Castell, JV ;
Jover, R .
CURRENT DRUG METABOLISM, 2003, 4 (04) :292-312
[9]   Vascular smooth muscle cell activation by C-reactive protein [J].
Hattori, Y ;
Matsumura, M ;
Kasai, K .
CARDIOVASCULAR RESEARCH, 2003, 58 (01) :186-195
[10]  
Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5